Nuclear overexpression of the E2F3 transcription factor in human lung cancer

Colin S Cooper, Andrew G Nicholson, Christopher Foster, Andrew Dodson, Sandra Edwards, Anne Fletcher, Toby Roe, Jeremy Clark, Anupam Joshi, Andrew Norman, Andrew Feber, Dongmei Lin, Yanning Gao, Janet Shipley, Shu-Jun Cheng

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)


The E2F3 transcription factor has an established role in controlling cell cycle progression. In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer. We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development. Since small cell lung cancers (SCLC) have one of the highest reported frequencies of functional abnormalities in the pRB protein (90%) of any human cancer, we wish to assess to what extent E2F3 would be overexpressed in this and other classes of human lung cancer.
Original languageEnglish
Pages (from-to)155-62
Number of pages8
JournalLung Cancer
Issue number2
Publication statusPublished - Nov 2006


  • Adenocarcinoma
  • Carcinoid Tumor
  • Carcinoma, Neuroendocrine
  • Carcinoma, Small Cell
  • Carcinoma, Squamous Cell
  • Cell Nucleus
  • E2F3 Transcription Factor
  • Gene Expression Regulation, Neoplastic
  • Genes, Retinoblastoma
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms
  • Oligonucleotide Array Sequence Analysis

Cite this